Gain Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

GANX$1.09+5.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets


· December 31, · December 31,
· · · 2024 · · 2023
Assets · ·
Current assets: · ·
Cash and cash equivalents	$10,385,863	$11,794,949
Marketable securities	—	4,999,704
Tax credits	271,079	242,577
Prepaid expenses and other current assets	945,536	741,638
Total current assets	11,602,478	17,778,868

Noncurrent assets:
Property and equipment, net	103,619	125,962
Internal-use software	134,268	193,375
Operating lease right-of-use assets	219,715	459,215
Restricted cash	31,695	34,021
Long-term deposits and other noncurrent assets	32,109	17,890
Total noncurrent assets	521,406	830,463
Total assets	$12,123,884	$18,609,331

Liabilities and stockholder's equity
Current liabilities:
Accounts payable	$946,259	$1,318,965
Operating lease liability - current	160,913	229,693
Other current liabilities	2,441,761	2,160,366
Deferred grant income - current	252,211	1,122,138
Loans - current	110,177	118,797
Total current liabilities	3,911,321	4,949,959

Noncurrent liabilities:
Defined benefit pension plan	443,623	307,454
Operating lease liability - noncurrent	53,598	229,855
Deferred grant income - noncurrent	47,441	94,786
Loans - noncurrent	328,327	449,053
Total noncurrent liabilities	872,989	1,081,148
Total liabilities	$4,784,310	$6,031,107

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of December 31, 2024 and 2023	$—	$—
Common stock, $0.0001 par value: 50,000,000 shares authorized; 27,132,588 and 16,206,680 shares issued and outstanding as of December 31, 2024 and 2023, respectively	2,713	1,621
Additional paid-in capital	88,779,318	73,113,079
Accumulated other comprehensive (loss) income	(247,549)	247,241
Accumulated deficit	(60,783,717)	(38,516,197)
Loss of the period	(20,411,191)	(22,267,520)
Total stockholders’ equity	7,339,574	12,578,224
Total liabilities and stockholders’ equity	$12,123,884	$18,609,331

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.